27
Participants
Start Date
July 13, 2017
Primary Completion Date
January 15, 2020
Study Completion Date
January 15, 2020
DSTA4637S
DSTA4637S will be administered as an IV infusion at 3 dose levels.
Placebo
Placebo matched to DSTA4637S IV infusion will be administered as specified.
SOC
Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
Duke University Medical Center, Durham
Hospital Universitario Ramon y Cajal, Madrid
Chungnam National University Hospital, Daejeon
Hospital Universitario Marques de Valdecilla, Santander
Hospital Universitario Virgen Macarena, Seville
Hospital Universitario Virgen del Rocio, Seville
William Beaumont Hospital, Royal Oak
Henry Ford Health System, Detroit
Gyeongsang National University Hospital, Gyeongsangnam-do
Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance
Asan Medical Center - Oncology, Seoul
Korea University Guro Hospital, Seoul
Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat
Hospital Mutua de Terrassa, Terrassa
Hospital del Mar, Barcelona
Hospital Clinic de Barcelona, Barcelona
Lead Sponsor
Genentech, Inc.
INDUSTRY